DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects
Related Experiment Video
Updated: Nov 8, 2025

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Published on: February 10, 2023
Nanda Kumar Jegadesan1, Dana Branzei2,3
1The FIRC Institute of Molecular Oncology, Italian Foundation for Cancer Research, 20139, Milan, Italy.
Abstract:
DDX11 encodes an iron-sulfur cluster DNA helicase required for development, mutated, and overexpressed in cancers. Here, we show that loss of DDX11 causes replication stress and sensitizes cancer cells to DNA damaging agents, including poly ADP ribose polymerase (PARP) inhibitors and platinum drugs. We find that DDX11 helicase activity prevents chemotherapy drug hypersensitivity and accumulation of DNA damage. Mechanistically, DDX11 acts downstream of 53BP1 to mediate homology-directed repair and RAD51 focus formation in manners nonredundant with BRCA1 and BRCA2. As a result, DDX11 down-regulation aggravates the chemotherapeutic sensitivity of BRCA1/2-mutated cancers and resensitizes chemotherapy drug-resistant BRCA1/2-mutated cancer cells that regained homologous recombination proficiency. The results further indicate that DDX11 facilitates recombination repair by assisting double strand break resection and the loading of both RPA and RAD51 on single-stranded DNA substrates. We propose DDX11 as a potential target in cancers by creating pharmacologically exploitable DNA repair vulnerabilities.
Insights
Loss of DDX11 DNA helicase causes replication stress, increasing cancer cell sensitivity to chemotherapy. DDX11 is crucial for DNA repair, making it a potential therapeutic target in various cancers.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- DDX11 encodes an iron-sulfur cluster DNA helicase essential for development.
- Mutations and overexpression of DDX11 are observed in various cancers.
- DDX11 plays a role in DNA replication and repair.
Purpose of the Study:
- To investigate the role of DDX11 in DNA repair and its impact on cancer cell sensitivity to DNA damaging agents.
- To elucidate the mechanism by which DDX11 influences DNA repair pathways.
- To evaluate DDX11 as a potential therapeutic target in cancer treatment.
Main Methods:
- Functional assays to assess replication stress and DNA damage accumulation.
- Analysis of homology-directed repair (HDR) and RAD51 focus formation.
- Investigating DDX11's role in double-strand break resection and RPA/RAD51 loading.
Main Results:
- Loss of DDX11 induces replication stress and sensitizes cancer cells to PARP inhibitors and platinum drugs.
- DDX11's helicase activity is critical for preventing hypersensitivity to chemotherapy and DNA damage.
- DDX11 acts downstream of 53BP1, mediating HDR and RAD51 focus formation independently of BRCA1/2.
- DDX11 down-regulation exacerbates sensitivity in BRCA1/2-mutated cancers and resensitizes resistant cells.
Conclusions:
- DDX11 is essential for efficient homologous recombination repair by facilitating DNA resection and stabilizing RPA/RAD51 on ssDNA.
- DDX11 deficiency creates pharmacologically exploitable DNA repair vulnerabilities in cancer.
- Targeting DDX11 may offer a novel therapeutic strategy for cancers, particularly those with BRCA1/2 mutations.
More Related Videos
Related Concept Videos
The DNA Replication Fork
Overview of DNA Repair
Chemically...
Overview of DNA Repair
Fixing Double-strand Breaks
Fixing Double-strand Breaks
Restarting Stalled Replication Forks

